Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Settlement, a potential problem.
I'm not sure we want to go back after ARM when we're licensing end users. After all, ARM jumped in at Toshiba's behalf (and I would let ARM try to defense again the same way they did the first time). I'd say get the 584 squared away and go back to end users. It seems to me this might be a sticking point when it comes to negotiating with the J's due to licensing the MMP as a whole. IMO the J's are using ARM and once you negate ARM's position the J's can't use it as an arguement IMO. How quickly this could be done in relation to the trial schedule, I don't know.
Share
New Message
Please login to post a reply